Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor? A Morphologic and Immunohistochemical Study

• Published in: American journal of clinical pathology Vol. 154; no. 1; pp. 133 - 141
• Main Authors: Wang, Lucy, Allison, Douglas, Shukla, Pratibha Sharma
• Format: Journal Article
• Language: English
• Published: Chicago Oxford University Press 01-07-2020
• Subjects: Cancer; Case studies; Cyclin D1; Diagnosis; Epithelial tumors; Gene expression; Genetic aspects; Genetic transformation; Immunohistochemistry; Malignancy; MDM2 protein; Next-generation sequencing; Oncology, Experimental; Ovarian tumors; Ovaries; Tumor suppressor genes; Tumors; United States
• ISSN: 0002-9173; 1943-7722
• DOI: 10.1093/AJCP/AQAA033

Objectives: To review the significance of MDM2 and cyclin D1 expression and loss of p16 expression in malignant and borderline Brenner tumors (BTs) of the ovary. Methods: We describe 2 new cases of ovarian BT, 1 malignant and 1 borderline. We studied MDM2, p16, and cyclin D1 expression by immunohistochemistry in the benign, borderline, and malignant components of these 2 cases and in 5 additional cases of benign BT. We also reviewed and summarized the literature on the clinical, immunohistochemical and molecular characteristics of borderline and malignant BTs (BdBTs and MBTs). Results: Nuclear expression of MDM2 was seen only in the MBT. Loss of p16 expression was seen in both BdBT and MBT. Cyclin D1 expression was in proportion to the degree of malignancy. Amplification of MDM2, loss of CDKN2A (p16-encoding gene), and amplification of CCND1 (cyclin D1-encoding gene) were confirmed by commercial next-generation sequencing in the case of MBT. Conclusions: We are the first to report immunohistochemical expression of MDM2 in an MBT. Amplification of MDM2 and loss of p16 expression may have a role in malignant transformation of BT. Key Words: Malignant Brenner tumor; Borderline Brenner tumor; MDM2; p16